reports
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PZG PARAMOUNT GOLD NEVADA CORP.
IRIX IRIDEX CORP.
VFF VILLAGE FARMS INTERNATIONAL IN
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
GRF ASTRONOVA INC.
NHF EAGLE CAPITAL GROWTH FUND INC
BCBP NEXPOINT CREDIT STRATEGIES FUN
RSSS BCB BANCORP INC.
NWPP RESEARCH SOLUTIONS
RFL NEW PEOPLES BANKSHARES INC.
ULBI RAFAEL HOLDINGS CL B
YMAB ULTRALIFE
IMUX Y-MABS THERAPEUTICS
AMPY IMMUNIC INC
INLX AMPLIFY ENERGY
ENX INTELLINETICS
DLHC INC.
COOK EATON VANCE NEW YORK MUNICIPAL BOND FUND
IMRX DALEIGH HOLDINGS CORP
XLO TRAEGER
NVCT INC.
GECC IMMUNEERING CORP
BARK XILIO THERAPEUTICS INC
NNUP NUVECTIS PHARMA INC
ERNA GREAT ELM CAPITAL CORP
GTE ORIGINAL BARK CO
GENK NOCOPI TECHS INC
SRBK ETERNA THERAPEUTICS INC.
NKGN GRAN TIERRA ENERGY INC.
PROP GEN RESTAURANT GROUP INC
ACTU SR BANCORP INC
SUNS NKGEN BIOTECH INC
EVM PRAIRIE OPERATING CO.
MBRX ACTUATE THERAPEUTICS INC.
SLS SUNRISE REALTY TRUST
WHLR EATON VANCE INSD CALIF MUN BD FD
HYMC MOLECULIN BIOTECH INC.
THAR SELLAS LIFE SCIENCES GROUP INC
RVYL WHEELER REAL ESTATE INVESTMENT TRUST INC.
INUV HYCROFT MINING HOLDING CORPORATION
CCIF THARIMMUNE INC.
RYVYL INC.
INUVO INC.
CARLYLE CREDIT INCOME FUND
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
FFIN FIRST FINANCIAL BANKSHARES INC
CAL CALERES INC.
CABO CABLE ONE INC.
PATK PATRICK INDUSTRIES INC.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
CC CHEMOURS CO.
IOVA IOVANCE BIOTHERAPEUTICS INC
QTRX QUANTERIX CORPORATION
RSSS RESEARCH SOLUTIONS
BHC BAUSCH HEALTH COMPANIES INC.
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
ETON ETON PHARMACEUTICALS
IMUX IMMUNIC INC
BLDR BUILDERS FIRSTSOURCE
FNWB INC.
AMPY FIRST NORTHWEST BANCORP
DCTH AMPLIFY ENERGY
ENX DELCATH SYSTEMS
TSHA EATON VANCE NEW YORK MUNICIPAL BOND FUND
SMMT TAYSHA GENE THERAPIES
HLMN SUMMIT THERAPEUTICS INC
COOK HILLMAN SOLUTIONS CORP.
AIRS TRAEGER
GECC INC.
TYRA AIRSCULPT TECHNOLOGIES INC
NNUP GREAT ELM CAPITAL CORP
BHRB TYRA BIOSCIENCES INC
DPG NOCOPI TECHS INC
RNXT BURKE & HERBERT BANK & TR/VA
GTE DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK RENOVORX INC
NKGN GRAN TIERRA ENERGY INC.
MNR SR BANCORP INC
NBBK NKGEN BIOTECH INC
NCDL MACH NATURAL RESOURCES LP
SDHY NB BANCORP INC.
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
WHLR PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
ABACUS GLOBAL MANAGEMENT INC.
WHEELER REAL ESTATE INVESTMENT TRUST INC.
- Jonathan Moreland
WSR WHITESTONE REIT
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MCY MERCURY GENERAL CORPORATION
FLO FLOWERS FOODS INC.
CTBI COMMUNITY TRUST BANCORP INC.
BUSE FIRST BUSEY CORPORATION
PATK PATRICK INDUSTRIES INC.
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CIA CITIZENS INC. CL A
BDL FLANIGAN'S ENTERPRISES INC.
CC CHEMOURS CO.
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
RSSS RESEARCH SOLUTIONS
RFL RAFAEL HOLDINGS CL B
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
REZI RESIDEO TECHNOLOGIES
IMUX INC.
FNWB IMMUNIC INC
XRX FIRST NORTHWEST BANCORP
AMPY XEROX HOLDINGS CORPORATION
VLA AMPLIFY ENERGY
TSHA ARBOR METALS
INNV TAYSHA GENE THERAPIES
SMMT INNOVAGE HOLDING
AFBI SUMMIT THERAPEUTICS INC
COOK AFFINITY BANCSHARES
TYRA INC.
BHRB TRAEGER
DPG INC.
VFC TYRA BIOSCIENCES INC
UHG BURKE & HERBERT BANK & TR/VA
GENK DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK VF CORPORATION
NKGN UNITED HOMES GROUP INC
NCDL GEN RESTAURANT GROUP INC
SDHY SR BANCORP INC
NEO NKGEN BIOTECH INC
JEQ NUVEEN CHURCHILL DIRECT LENDING CORP
LION PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
SLS NEO CORPORATE PUBLIC COMPANY LIMITED
ABL THE JAPAN EQUITY FUND
INC.
LIONSGATE STUDIOS CORP
SELLAS LIFE SCIENCES GROUP INC
ABACUS GLOBAL MANAGEMENT INC.
- Jonathan Moreland
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
BUSE FIRST BUSEY CORPORATION
PATK PATRICK INDUSTRIES INC.
CC CHEMOURS CO.
IMUX IMMUNIC INC
BIGC BIGCOMMERCE HOLDINGS
ADV INC.
STGW ADVANTAGE SOLUTIONS INC (A)
GRNT STAGWELL INC
SRBK GRANITE RIDGE RESOURCES INC
SR BANCORP INC
EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered D...
Issuer: Immunic AG / Key word(s): Financing Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments 09.04.2025 / 14:10 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments NEW YORK, April 9, 2025 /PRNewswire/ — (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmu...
EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conf...
Issuer: Immunic AG / Key word(s): Conference Immunic, Inc. to Participate in Scientific and Industry Conferences in April 01.04.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in Scientific and Industry Conferences in April NEW YORK, April 1, 2025 – (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences...
EQS-News: Immunic to Participate in Scientific and Investor Conference...
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in March 03.03.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in March NEW YORK, March 3, 2025 – (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:...
EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIM...
Issuer: Immunic AG / Key word(s): Conference/Study Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis 26.02.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models – – Top-Line Data...
EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase ...
Issuer: Immunic AG / Key word(s): Study results Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing 20.02.2025 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing – New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Depe...
EQS-News: Immunic to Participate in Investor and Scientific Conference...
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in February 04.02.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences in February NEW YORK, February 4, 2025 – (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences i...
EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milesto...
Issuer: Immunic AG / Key word(s): Miscellaneous Immunic Highlights 2024 Accomplishments and Upcoming Milestones 07.01.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Highlights 2024 Accomplishments and Upcoming Milestones – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Com...
EQS-News: Immunic, Inc. to Participate in Investor Conference in Decem...
Issuer: Immunic AG / Key word(s): Conference Immunic, Inc. to Participate in Investor Conference in December 26.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in Investor Conference in December NEW YORK, November 26, 2024 – (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fire...
EQS-News: Immunic Announces Publication of Data From Phase 1/1b Clini...
Issuer: Immunic AG / Key word(s): Scientific publication Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology 13.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology – Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK, Novem...
EQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results a...
Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update 07.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned – – Ongoing, Twin Phase 3 ENSU...
EQS-News: Immunic, Inc. to Announce Financial Results for the Third Qu...
Issuer: Immunic AG / Key word(s): Miscellaneous Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update 31.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Announce Financial Results for the Third Quarter EndedSeptember 30, 2024, and Provide Corporate Update – Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK, October 31, 2024 – (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small ...
EQS-News: Immunic to Participate in Industry, Scientific and Investor...
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Industry, Scientific and Investor Conferences in November NEW YORK, October 29, 2024 – (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scienti...
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Ph...
Issuer: Immunic AG / Key word(s): Study results Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis 22.10.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis – Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met – ...
EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th C...
Issuer: Immunic AG / Key word(s): Conference Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis 18.09.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis – Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Tria...
EQS-News: Immunic Announces First Patient Enrolled in Investigator-Spo...
Issuer: Immunic AG / Key word(s): Study Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome 04.09.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome – Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.